Constance, Germany

Armin Zuelch



Average Co-Inventor Count = 5.8

ph-index = 2

Forward Citations = 13(Granted Patents)


Company Filing History:


Years Active: 2010-2011

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: **Armin Zuelch: Innovator in Protein Kinase Inhibitors**

Introduction

Armin Zuelch is a dedicated inventor based in Constance, Germany. With a strong focus on the development of advanced pharmaceuticals, he has made significant contributions to the field, particularly in the realm of protein kinase inhibitors.

Latest Patents

Zuelch holds two notable patents that reflect his expertise and innovative thinking. The first patent, titled "4,6-disubstituted pyrimidines and their use as protein kinase inhibitors," presents novel pyrimidine derivatives that demonstrate effective inhibition of protein kinases, specifically targeting one or more isoforms of the protein kinase B/Akt. His second patent, involving "Pyrazolo[1,5-c]pyrimidines," describes compounds expected to be beneficial in the treatment of (hyper)proliferative diseases and disorders responsive to the induction of apoptosis.

Career Highlights

Currently, Armin Zuelch is affiliated with Bayer Schering Pharma AG, a prominent company recognized for its contributions to healthcare and pharmaceuticals. His work at Bayer highlights his commitment to advancing medical science through innovative solutions.

Collaborations

Throughout his career, Zuelch has collaborated with talented professionals including Thomas Baer and Thomas Maier. These partnerships underscore the collaborative spirit in scientific research and innovation, fostering the development of groundbreaking therapies.

Conclusion

Armin Zuelch's contributions to the field of pharmaceuticals exemplify the innovative spirit of today’s inventors. Through his patents and collaborations, he is making strides in the fight against serious diseases, showcasing the importance of research and development in healthcare advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…